Biopure back in Nasdaq compliance

Biopure Corp., a Cambridge drug company that develops oxygen therapeutics, said that the symbol for its Class A common stock will revert from BPURD to BPUR at the opening of today's trading on the Nasdaq Stock Market.

Two weeks ago, the company said it had been notified by Nasdaq that it had regained compliance with the $1 minimum bid price requirement for continued listing on Nasdaq.
(By Chris Reidy, Globe staff)